MIRA Pharmaceuticals, Inc.
MIRA
$0.84
$0.03724.63%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.58M | 1.01M | 1.12M | 1.01M | 2.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.44M | 2.08M | 1.73M | 1.77M | 3.06M |
| Operating Income | -2.44M | -2.08M | -1.73M | -1.77M | -3.06M |
| Income Before Tax | -2.40M | -2.04M | -1.69M | -1.72M | -5.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.40M | -2.04M | -1.69M | -1.72M | -5.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.40M | -2.04M | -1.69M | -1.72M | -5.79M |
| EBIT | -2.44M | -2.08M | -1.73M | -1.77M | -3.06M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.14 | -0.14 | -0.11 | -0.09 | -0.39 |
| Normalized Basic EPS | -0.09 | -0.08 | -0.07 | -0.05 | -0.24 |
| EPS Diluted | -0.14 | -0.14 | -0.11 | -0.09 | -0.39 |
| Normalized Diluted EPS | -0.09 | -0.08 | -0.07 | -0.05 | -0.24 |
| Average Basic Shares Outstanding | 16.56M | 15.07M | 14.78M | 19.71M | 14.78M |
| Average Diluted Shares Outstanding | 16.56M | 15.07M | 14.78M | 19.71M | 14.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
